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Female condoms: new choices, old questions
As the only methods available for dual protection against 
pregnancy and sexually transmitted infections (STIs), 
male and female condoms have a vital role in sexual 
and reproductive health. Mags Beksinska and colleagues 
therefore are to be commended for their randomised 
crossover trial in this issue,1 which establishes that three 
types of female condom (Woman’s Condom, VA w.o.w., 
and Cupid) have similarly low rates of self-reported 
problems as the FC2, the only female condom approved 
by the US Food and Drug Administration (FDA). 
Beksinska and colleagues’ ﬁ ndings will fulﬁ l a key step for 
public-sector programmes to procure the new products 
for distribution in developing countries. Despite this 
achievement, however, critical questions remain.
First, will an expansion of choices in female condom 
types lead to increased use of these products? Beksinska 
and colleagues suggest that increasing the variety 
of female condom devices available could increase 
method coverage and, consequently, reduce incidence 
of unintended pregnancy and disease. In general, having 
a wider selection of contraceptive methods that diﬀ er 
in important attributes (eg, cost, duration of eﬀ ect, 
timing with respect to coitus, and real or perceived 
side-eﬀ ects) would be expected to increase overall use.2 
Yet randomised trials in four countries found that men 
given a choice of types of male condom had similar rates 
of unprotected sex3 and STIs3,4 as those not oﬀ ered a 
choice of condoms. The male condom products oﬀ ered 
in the intervention groups might not have varied 
suﬃ  ciently to aﬀ ect rates of use. Do the new types of 
female condoms oﬀ er enough distinct advantages (eg, 
improved designs and reduced cost) to increase the 
number of sex acts protected?
Second, are diﬀ erent data required to move policy 
makers and providers, and ultimately women, to 
embrace the female condom? Some have argued that 
low uptake of female condoms does not stem from 
negative perceptions among users as much as higher-
level lack of support for the device on the part of policy 
makers, with resultant insuﬃ  cient procurement of 
supplies and inadequate promotion of the product 
to women.5 Yet the anaemic response is perhaps not 
surprising. The FDA product labelling for the FC2 
recommends its use for disease protection only if latex 
male condoms will not be used. This qualiﬁ er stems from 
a lack of comparative eﬀ ectiveness data between female 
and male condoms, rather than evidence of the former’s 
inferior protection. Given this labelling, hesitancy to 
embrace the female condom is understandable; data 
to show whether female condoms are as eﬀ ective for 
disease prevention as male condoms might increase 
support among decision makers.
Third, do regulatory and international bodies require 
the best type of data for measuring non-inferiority? 
Beksinska and colleagues measured self-reports of 
product failure (deﬁ ned as use problems such as 
breakage, slippage, invagination, and misdirection) 
to satisfy a regulatory hurdle for product approval. 
However, the questionable accuracy of self-reported 
condom data makes this a poor proxy for pregnancy 
and disease incidence.6 For example, women might 
have been diﬀ erentially able to detect, and thus report, 
problems with condom performance. As an alternative 
to self-report, detection of prostate-speciﬁ c antigen 
(PSA) is a cost-eﬀ ective method (estimated at US$4·50 
per rapid test and $20 per quantitative test6) to measure 
objectively women’s exposure to semen. Two trials 
assessed the eﬀ ectiveness of the original female condom 
in the USA relative to male condoms by having women 
self-swab to compare PSA concentrations in specimens 
collected immediately before and after coital acts using 
the study condoms.7,8 This design could provide superior 
data in future trials to assess device eﬀ ectiveness.
Finally, will female condoms follow the trajectory 
of tampons or of menstrual cups? Globally, use of 
female condoms has remained disappointingly low: 
the product represents only 0·7% of total condoms 
distributed by donor countries in 2010.9 Are female 
condoms like tampons in North America and Europe, 
which languished largely unused for nearly 30 years 
before eventually becoming an enormously popular—
perhaps indispensable—reproductive health product?10 
Or are they more analogous to menstrual cups, which 
have been around for decades, but have been adopted 
by only a small subset of women, despite numerous 
design tweaks. Implementation research to understand 
and replicate the enthusiastic uptake among some 
female condom users is critical to gauge the amount 
of funding and eﬀ ort that should be invested into the 
device’s development and promotion.
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In summary, female condoms could bring great 
beneﬁ t in pregnancy and disease prevention, and the 
ﬁ ndings reported by Beksinska and colleagues will be 
useful as advocates work to expand female condom 
choices available worldwide. Barriers at many levels—
cost, availability, lack of evidence of health eﬀ ect, and 
promotion relative to other products—have hampered 
women’s adoption of female condoms. Answering 
the critical questions posed here might better equip 
country-level sexual and reproductive health advocates 
and funding agencies to expand access to female 
condoms, and catapult the method to more widespread 
use by women wishing to prevent pregnancy and STIs.
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